Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus monthly Actonel after prior alendronate in postmenopausal osteoporosis
NL-OMON38276Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in postmenopausal osteoporosis comparing Denosumab every 6 months with Actonel monthly (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2009; status: active, not recruiting.
02
Drugs
denosumabrisedronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NL-OMON38276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38276.